Healthmap Solutions – a national population health management company focused on kidney disease – recently announced that it has raised $100 million to support the ongoing expansion of its business. And Healthmap has grown rapidly with its health plan customers and is currently contracted to serve over 160,000 individuals with kidney disease.
This funding round will provide the company with the resources required for newly awarded business and the balance sheet strength to support the growing portion of Healthmap’s covered lives contracted under capitated arrangements. And Healthmap is contracted to manage over $3 billion in healthcare spend through risk-based arrangements with several of the country’s leading health plans and at-risk providers.
The company’s growth is a result of its proven ability to improve care and lower costs for polychronic patients through the use of advanced technology, predictive analytics, machine learning, clinical expertise, and face-to-face interactions with providers and members. And the company’s approach has been effective across Medicare, Medicaid, and commercial populations living in disparate geographies. Healthmap’s highly scalable business model has enabled the company to make a positive impact on broad populations and has also demonstrated its financial durability and predictability. After ongoing investments in rapid growth, Healthmap expects to begin generating earnings in 2023.
The funds managed by Healthmap’s largest investor WindRose Health Investors led the financing along with participation from existing investors.
KEY QUOTE:
“We are grateful for the ongoing support of our investor group and excited to have ample resources to maintain our rapid growth. We believe that Healthmap has built a differentiated approach to managing chronic kidney disease. It is rewarding to see the market’s enthusiasm for our program and the positive impact we are having on patients’ lives.”
― Eric Reimer, Healthmap’s Chief Executive Officer
